Navigation Links
Xencor, Inc. Announces Closing of Initial Public Offering
Date:12/6/2013

MONROVIA, Calif., Dec. 6, 2013 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR) today announced the closing of its initial public offering of 14,639,500 shares of its common stock at an initial public offering price of $5.50 per share, which includes the exercise in full by the underwriters of their option to purchase up to 1,909,500 additional shares of common stock. Xencor's common stock is listed on The NASDAQ Global Market under the trading symbol "XNCR." All of the shares in the offering were offered by Xencor. Xencor estimates net proceeds from the offering to be approximately $72.4 million, after deducting underwriting discounts and commissions and estimated offering expenses.

Credit Suisse Securities (USA) LLC and Leerink Swann LLC are acting as joint book-running managers of the offering. Wedbush PacGrow Life Sciences is acting as a co-manager for the offering.

A registration statement relating to the securities being sold in this offering was declared effective by the U.S. Securities and Exchange Commission on December 2, 2013. The offering was made only by means of a written prospectus forming part of the effective registration statement. A copy of the final prospectus may be obtained from Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, by calling toll-free (800) 221-1037, or by emailing newyork.prospectus@credit-suisse.com; or Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110, or by email at Syndicate@Leerink.com, or by phone at (800) 808-7525.

This news release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Xencor, Inc.
Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Currently, five antibodies are in clinical development internally and with partners that have been engineered with Xencor's XmAb technology.  Xencor's internally-discovered programs include XmAb5871, in Phase 1b/2a clinical trials for the treatment of Rheumatoid arthritis and lupus, XmAb7195 in preclinical development for the treatment of asthma, and XmAb5574/MOR208 which has been licensed to Morphosys AG and is in Phase 2 clinical trials for the treatment of acute lymphoblastic leukemia and non-Hodgkin lymphoma. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. Xencor partners include Amgen, Merck, Janssen R&D LLC and Boehringer Ingelheim.


'/>"/>
SOURCE Xencor, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen Therapeutics, Inc. Announces the Closing of its Offering of $115 Million of Convertible Senior Notes
2. Concord Medical Announces the Closing of Acquisition of Its Shares by CEO and COO from Other Shareholders
3. Osseon Announces New Regional Sales Director
4. UPCOMING DEADLINE: Levi & Korsinsky, LLP Announces Class Action Against ARIAD Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 9, 2013 -- ARIA
5. EarlySense Announces Patient Rest Indicator for Better Patient Supervision at Night
6. Lilly Announces Edivoxetine Did Not Meet Primary Endpoint of Phase III Clinical Studies as Add-On Therapy for Major Depressive Disorder
7. Cyberonics Announces Expansion of Share Repurchase Program By An Additional One Million Shares
8. Ambit Announces Participation At Oppenheimer 24th Annual Healthcare Conference
9. NeuroSigma Announces Receipt of Notice of Allowance of U.S. Patent Application Related to External Trigeminal Nerve Stimulation (eTNS) for the Treatment of Epilepsy and other Neurological Disorders
10. Soligenix Announces Initiation of a Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
11. MiMedx Announces Next Steps After Discussions With The FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... CAMBRIDGE, Mass. , Jan. 18, 2017  Tarix ... Drug Administration has granted a Rare Pediatric Disease (RPD) ... treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB), a rare ... for RDEB and treatment is limited to supportive care. ... supplements the Orphan Drug Designation previously granted by the ...
(Date:1/18/2017)... Jan. 18, 2017  Robust competition in the ... discounts on medicine prices, according to a new ... study is among the first to examine the share ... manufacturers, pharmacy benefit managers (PBMs), health plans and other ... study is the first to show what happens when ...
(Date:1/17/2017)... 17, 2017 North America Insulin Delivery Market ... "North America Insulin Delivery Market Outlook to 2022", provides ... market. The report provides value, in millions of US ... market segments - Insulin Pens, Insulin Pumps, Insulin Syringes ... provides company shares and distribution shares data for each ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... , ... Gym Source, America’s leading retailer of premium residential and commercial fitness ... Miami, FL. , “We are elated to be opening this new showroom,” explains Tom ... to give clients a seamless and motivating shopping experience.” , Every fitness journey is ...
(Date:1/17/2017)... ... January 17, 2017 , ... Today, to help ... Francis re-releases powerfully uplifting interview with medical expert and prolific author, Dr. Bernie ... pass through tough times, Dr. Bernie Siegel energizes listeners to live life with ...
(Date:1/17/2017)... ... , ... Kevin Harrington (one of the original Sharks from mega-hit reality series ... topic of Beauty and Personal Care. , Everyone makes New Year’s ... commit to these changes than beginning with personal care and beauty products? AsSeenOnTV.pro will ...
(Date:1/17/2017)... San Clemente, CA (PRWEB) , ... January 17, ... ... San Diego County, as well as Palm Desert, is opening a new office ... of Brainsway deep transcranial magnetic stimulation (dTMS) in Southern California, successfully treating individuals ...
(Date:1/17/2017)... Metairie, Louisiana (PRWEB) , ... January 17, 2017 ... ... JenCare Senior Medical Center joined the Peoples Health network on Dec. 1, ... Medicare beneficiaries. , “JenCare Senior Medical Center is an exciting addition to our ...
Breaking Medicine News(10 mins):